Japan’s CEA Scheme: How It Works And Impact So Far
Average 2.7% Cut
Japan has announced the latest evaluation results under its cost effectiveness assessment scheme. But how does it work and how much have prices been revised so far under the four-year-old program following discussions between pharma firms and authorities?
You may also be interested in...
Japan adds a batch of new drugs, including Wegovy, to the national health insurance reimbursement tariff, but discussions over Leqembi for Alzheimer’s are still ongoing, with indications that repricing could be possible if demand expands quickly.
Japan's latest batch of product approvals includes high-profile Alzheimer's drug Leqembi (lecanemab), along with Alhemo (concizumab) for hemophilia, Phozevel (tenapanor) for hyperphosphatemia and others. Eyes are now on the shape of use guidelines and monitoring requirements for Leqembi, along with how its extended NHI reimbursement pricing process will develop. All going well, it could reach the market by the end of the year.
Despite repeated warnings by regulatory authorities and physicians’ associations, the demand for easy diet aids is impacting the supply of GLP-1 receptor antagonists in Japan.